hVIVO PLC
LSE:HVO

Watchlist Manager
hVIVO PLC Logo
hVIVO PLC
LSE:HVO
Watchlist
Price: 19.5 GBX -1.02% Market Closed
Market Cap: 132.7m GBX
Have any thoughts about
hVIVO PLC?
Write Note

hVIVO PLC
Investor Relations

hVIVO PLC provides pharmaceutical development services. The firm is engaged in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The company provides end-to-end early clinical development services to its client base, which includes global biopharma companies. The company offers a portfolio of approximately 10+ human challenge models to test a range of infectious and respiratory disease products, challenge agent manufacturing, specialist drug development, and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The company offers additional clinical field trial services, such as patient recruitment and clinical trial site services. The company runs challenge studies in from its Whitechapel quarantine clinic, and its QMB clinic with its specialized on-site virology and immunology laboratory.

Show more

Earnings Calls

No Earnings Calls Available

Management

Dr. Yamin Mohammed Khan Ph.D.
CEO & Director
No Bio Available
Mr. Stephen Pinkerton
CFO & Executive Director
No Bio Available
Mr. Andrew Catchpole
Chief Scientific Officer
No Bio Available
Ms. Teja Marathe-Sarvadikar
Head of QA
No Bio Available

Contacts

Address
London
Queen Mary BioEnterprises Innovation Centre, 42 New Road
Contacts
+442890737900
hvivo.com